Quantcast

Latest Hydrocodone Stories

2014-07-29 08:34:16

WAYNE, Pa., July 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Egalet's website. Please...

2014-07-08 08:31:18

Anticipated FDA action set for October 2014 STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-05-28 08:32:01

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., May 28, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to...

2014-05-21 08:28:28

CutisPharma has moved to a larger facility to support growth WILMINGTON, Mass., May 21, 2014 /PRNewswire/ -- CutisPharma, Inc. announced its move to a new location at 841 Woburn St. Wilmington, MA. "We are pleased to announce our relocation to a larger facility to support our record growth," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "The move will help to maintain our expansion, particularly in the areas of Research and Development, Customer Service, and...

2014-05-07 08:33:35

CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the...

2014-04-30 23:21:39

New hydrocodone painkiller could come with an increased risk of addiction. Fort Lauderdale, Fla. (PRWEB) April 30, 2014 A brand-new painkiller has been released, and it could pose a very serious threat to the public. Zohydro is the first painkiller that is made up only of hydrocodone, and available dosage amounts go as high as 50 milligrams. This is five times as much as comparable drugs. Destination Hope's Florida drug rehab is concerned that a lack of education and easy access to...

2014-04-30 12:30:02

Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Benzoic...

2014-04-30 08:33:23

Data from Clinical Drug-liking Studies Also to be Presented at APS Today STAMFORD, Conn., April 30, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate...

2014-04-29 23:02:48

A Forever Recovery, an open-ended drug and alcohol treatment program that gets clients off to a great start and gives them a solid foundation in recovery they can believe in, is focusing on the new FDA approved painkiller Zohydro ER in its latest blog post. Battle Creek, MI (PRWEB) April 29, 2014 A Forever Recovery, an open-ended drug and alcohol treatment program that gets clients off to a great start and gives them a solid foundation in recovery they can believe in, is focusing on the...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related